Drug Trial Radar · NCT00223977
2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
Last checked: Nov 20, 2026Latest source record: Jul 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Dec 2003
Primary completion
Nov 2004
Study completion Feb 2008
Sponsor
- Lead sponsor
- Watson PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.
Conditions
- Iron Deficiency Anemia
Interventions
Sodium Ferric Gluconate ComplexDrug
125 mg weekly x 8 weeks
Sodium Ferric Gluconate ComplexDrug
250 mg weekly x 4
Oral IronDrug
325 mg ferrous sulfate orally three times daily x 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- HemoglobinTime frame: Baseline to 5 weeks and 9 weeks
Locations
43 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mesa, Arizona
Site not named
Los Angeles, California
Site not named
Torrance, California
Site not named
New Haven, Connecticut
Site not named
Evanston, Illinois
Site not named
Shreveport, Louisiana
Site not named
Springfield, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Royal Oak, Michigan
Site not named
St Louis, Missouri
Site not named
New York, New York
Site not named
Chapel Hill, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Tulsa, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Sioux Falls, South Dakota
Site not named
Dallas, Texas
Site not named
Richmond, Virginia
Site not named
Sofia, Bulgaria
Site not named
Varna, Bulgaria
Site not named
Kelowna, Canada
Site not named
Kitchener, Canada
Site not named
London, Canada
Site not named
Scarborough, Canada
Site not named
Toronto, Canada
Site not named
Zagreb, Croatia
Site not named
Bangalore, India
Site not named
Chandigarh, India
Site not named
Chennai, India
Site not named
Hyderabad, India
Site not named
Lucknow, India
Site not named
Mahīm, India
Site not named
New Delhi, India
Site not named
Col. Toriello Guerra, Mexico
Site not named
Durango, Mexico
Site not named
Mexico City, Mexico
Site not named
Monterrey, Mexico
Site not named
Tlalpan, Mexico
Site not named
Zapopan, Mexico
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.